{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=16",
    "query": {
      "intervention": "combined treatment",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 13961,
    "total_pages": 1397,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T19:24:08.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00920985",
      "title": "US Cycle Control and Blood Pressure Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "Gestodene/EE (FC Patch Low, BAY86-5016)",
          "type": "DRUG"
        },
        {
          "name": "Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 346,
      "start_date": "2009-06",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 28,
      "location_summary": "Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 25 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920985"
    },
    {
      "nct_id": "NCT00002168",
      "title": "A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Indinavir sulfate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 200,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-10-02",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 12,
      "location_summary": "Berkeley, California • Torrance, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002168"
    },
    {
      "nct_id": "NCT02453191",
      "title": "TVEC and Preop Radiation for Sarcoma (4 ml Dose)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-07-13",
      "completion_date": "2023-03-10",
      "has_results": true,
      "last_update_posted_date": "2024-06-20",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02453191"
    },
    {
      "nct_id": "NCT01166126",
      "title": "Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucosal Melanoma",
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "selumetinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2010-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-15",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01166126"
    },
    {
      "nct_id": "NCT03071276",
      "title": "Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "methotrexate/hydrocortisone/cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "Up to 24 Years"
      },
      "enrollment_count": 37,
      "start_date": "2016-01-14",
      "completion_date": "2019-04-30",
      "has_results": true,
      "last_update_posted_date": "2020-05-22",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071276"
    },
    {
      "nct_id": "NCT04446117",
      "title": "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Prostate Cancer",
        "Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 575,
      "start_date": "2020-10-19",
      "completion_date": "2026-10-16",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Duarte, California • Fullerton, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Marina del Rey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04446117"
    },
    {
      "nct_id": "NCT00375310",
      "title": "Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Adenocarcinoma of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Gemcitabine, Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2006-09",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-02-29",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00375310"
    },
    {
      "nct_id": "NCT03684213",
      "title": "Local Antioxidant Therapy Vasoconstriction Effects in Different Races",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Cardiovascular Risk Factor",
        "Vasoconstriction"
      ],
      "interventions": [
        {
          "name": "Control (Norepinephrine)",
          "type": "DRUG"
        },
        {
          "name": "Norepinephrine + Ascorbic Acid",
          "type": "DRUG"
        },
        {
          "name": "Norepinephrine + L-NAME",
          "type": "DRUG"
        },
        {
          "name": "Norepinephrine + L-NAME + Ascorbic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas at Arlington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 22,
      "start_date": "2018-10-15",
      "completion_date": "2024-06-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03684213"
    },
    {
      "nct_id": "NCT02339324",
      "title": "Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab and high dose interferon alfa-2b (HDI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yana Najjar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2015-03-06",
      "completion_date": "2019-11-02",
      "has_results": false,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339324"
    },
    {
      "nct_id": "NCT05172258",
      "title": "Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Oral Cavity Squamous Cell Carcinoma",
        "Metastatic Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-07-26",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-15T19:24:08.909Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Irvine, California • Lancaster, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05172258"
    }
  ]
}